Many studies in mouse models of PD have found that treatment with 1,25(OH)2D3 resulted in an increase of vitamin D receptor (VDR) expression and tyrosine hydroxylase (TH), as well as increasing the dopamine content (Smith et al., 2006; Jiang et al., 2014; Li et al., 2015). This evidence concerns the gene VDR and Parkinson disease.